Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PLM-101 |
Synonyms | |
Therapy Description |
PLM-101 inhibits FLT3 and RET, potentially resulting increased cell cycle arrest and apoptosis and decreased tumor growth (PMID: 37392657). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PLM-101 | PLM101|PLM 101 | FLT3 Antibody 5 RET Inhibitor 53 | PLM-101 inhibits FLT3 and RET, potentially resulting increased cell cycle arrest and apoptosis and decreased tumor growth (PMID: 37392657). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins FLT3 D835Y | hematologic cancer | sensitive | PLM-101 | Preclinical - Cell culture | Actionable | In a preclinical study, PLM-101 inhibited proliferation in cells expressing FLT3 D835Y in the context of a FLT3-ITD mutation in culture (PMID: 37392657). | 37392657 |
FLT3 exon 14 ins | hematologic cancer | sensitive | PLM-101 | Preclinical - Cell culture | Actionable | In a preclinical study, PLM-101 inhibited kinase activity and proliferation in cells expressing a FLT3-ITD mutation in culture (PMID: 37392657). | 37392657 |
FLT3 exon 14 ins FLT3 F691L | hematologic cancer | sensitive | PLM-101 | Preclinical - Cell culture | Actionable | In a preclinical study, PLM-101 inhibited proliferation in cells expressing FLT3 F691L in the context of a FLT3-ITD mutation in culture (PMID: 37392657). | 37392657 |
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | PLM-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PLM-101 induced apoptosis and cell cycle arrest and inhibited Flt3 phosphorylation, downstream signaling, and proliferation in acute myeloid leukemia cell lines harboring a FLT3-ITD mutation in culture and inhibited tumor growth in cell line xenograft models (PMID: 37392657). | 37392657 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|